Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Key Benefits Marked reduction in body weight in clinical studies, with high-impact results in obesity
Initially developed by Novo Nordisk in the 1990s, Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) selective agonist of the GHS-R1a receptor (ghrelin receptor), responsible for stimulating pulsatile growth hormone secretion without the cross-side effects characteristic of non-selective GHRPs
A key double-blind, placebo-controlled phase II study conducted over 72 weeks recruited 320 individuals with histologically confirmed NASH and liver fibrosis classified as stage F1 to F3
Follow a Healthy Diet Often, stubborn fat occurs after GLP1 treatments simply because you are following an unhealthy diet
US$ 20.93
US$ 27.87
US$ 28.06
US$ 27.90
US$ 28.62
US$ 24.14
